Kalaris Therapeutics Inc. Common Stock (KLRS)
Stock · NASDAQ · Health Care
$4.03as of 8/28/2026
Price chart
Open in TradingViewActive signals
Resistance level
$4.06
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
About KLRS
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular ret…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 20
- Website
- kalaristx.com/
Fundamentals
- 1-day range
- $4.04$4.31
- Market cap
- $99.69M
- P/E (trailing)
- —
- P/E (forward)
- -2.50
- EPS (trailing)
- $-2.21
- Dividend yield
- —
- Beta
- 0.44
- Avg. volume
- 269.1K
52-week range
$3.03$11.88
Next earnings: August 7, 2025 · EPS estimate $-0.52confirmed
Forecasts
7 analyst ratings
Buy 86%
Hold 14%
Sell 0%
1-year price forecast
High
$25
+520.3%
Median
$20
+396.3%
Low
$7
+73.7%
Kalaris Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- KLRSKalaris Therapeutics Inc. Common Stock$4.03▼ 1.71%Market cap $99.69MP/E —$3.03$11.88
- CGTXCognition Therapeutics Inc. Common Stock$1.03▼ 3.30%Market cap $101.13MP/E —$0.5501$2.79
- PTHSPelthos Therapeutics Inc. Common Stock$24.46▼ 2.16%Market cap $102.36MP/E —$18.19$37.5
- BDTXBlack Diamond Therapeutics Inc. Common Stock$2.23▼ 1.76%Market cap $110.02MP/E —$1.6$4.94
- ENGNenGene Therapeutics Inc. Common Stock$1.83▼ 4.19%Market cap $120.58MP/E —$1.4$12.25
- ATRAAtara Biotherapeutics Inc. Common Stock$9.16▼ 0.97%Market cap $74.33MP/E —$3.92$19.15
- ELOXEloxx Pharmaceuticals Inc. Common Stock$15.07▼ 12.69%Market cap $71.48MP/E —$0$23.4
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $4.03 | ▼ 1.71% | $3.03$11.88 |
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $1.03 | ▼ 3.30% | $0.5501$2.79 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $24.46 | ▼ 2.16% | $18.19$37.5 |
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $2.23 | ▼ 1.76% | $1.6$4.94 |
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.83 | ▼ 4.19% | $1.4$12.25 |
| ATRA Atara Biotherapeutics Inc. Common Stock | $74.33M | — | $9.16 | ▼ 0.97% | $3.92$19.15 |
| ELOX Eloxx Pharmaceuticals Inc. Common Stock | $71.48M | — | $15.07 | ▼ 12.69% | $0$23.4 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) EstimateBenzinga · 8/11/2026
Insider Activity
Insider Actions →Acquired
574.7K
Disposed
68.8K
- Vandekop Amy O'Leary · August 27, 2026 · Grant10.0K
- KEATING LAURIE · August 1, 2026 · Grant18.0K
- Bayko Liisa Ann · July 20, 2026 · Grant220.0K
- Leone D. Patterson · June 3, 2026 · Grant9.0K
- Napoleone Ferrara · June 3, 2026 · Grant9.0K
- Dybbs Michael · June 3, 2026 · Grant9.0K
- Jovan-Embiricos Morana · June 3, 2026 · Grant9.0K
- Hallal David · June 3, 2026 · Grant9.0K
- ADAMIS ANTHONY P · June 3, 2026 · Grant9.0K
- Srinivas Akkaraju · June 3, 2026 · Grant9.0K
- Srinivas Akkaraju · May 20, 2026 · J4.5K
- Srinivas Akkaraju · May 20, 2026 · J14.9K
- Srinivas Akkaraju · May 20, 2026 · J66.9K
- Srinivas Akkaraju · May 20, 2026 · Buy244.3K @ $4.83
- Brett R. Hagen · March 20, 2026 · Sale1.9K @ $6.72
Institutional Ownership
March 31, 2026
- Total shares held
- 18.54M
- Total value held
- $106.90M
- Institutional holders
- 55
Top holders this quarter
- Unknown12.95M
- Unknown1.30M
- Unknown700.0K
- Unknown572.7K
- Unknown435.8K
- Unknown360.0K
- Unknown295.8K
- Unknown255.3K
- Unknown135.6K
- Unknown118.9K
See the full, filterable feed with live charts on the MarketWall dashboard.